Business Context and Reporting Period
This Form 8-K filing by National Research Corporation (NRC Health) reports on events occurring on May 7, 2025, specifically the conclusion of the Company's Annual Meeting of Shareholders. The filing details the ratification of corporate governance matters, including director elections, auditor ratification, executive compensation approval, and the adoption of a new equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder votes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent 10-K or 10-Q filings for financial statements.
Material Changes and Shareholder Votes
The filing documents the final results of four proposals voted upon at the Annual Meeting:
- Director Elections: Donald M. Berwick and Stephen H. Lockhart were elected to three-year terms expiring in 2028. Both received overwhelming support with over 20.9 million votes "For" each.
- Auditor Ratification: Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for 2025 with 21.7 million votes "For".
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 20.7 million votes "For".
- Equity Incentive Plan: The 2025 Omnibus Incentive Plan was approved with 16.9 million votes "For". This plan replaces the 2006 Equity Incentive Plan and the 2004 Non-Employee Director Stock Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, market outlook, or specific risk factors. The primary operational change noted is the implementation of the 2025 Omnibus Incentive Plan, effective May 7, 2025, which will govern future equity awards.
Key Facts for Investor Verification
- Verify the specific terms and share limits of the newly approved 2025 Omnibus Incentive Plan in the Proxy Statement filed on April 10, 2025.
- Note the significant number of "Against" votes (approx. 4 million) on the Omnibus Incentive Plan compared to other proposals, indicating some shareholder dissent on equity structure.
- Confirm the tenure of the newly elected directors, Donald M. Berwick and Stephen H. Lockhart, which extends through the 2028 annual meeting.
- Review the Company's latest periodic reports (10-K/10-Q) for financial data, as this 8-K contains no financial metrics.